Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.

Pitts TM, Simmons DM, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Tentler JJ, Cittelly D, Ormond DR, Messersmith WA, Eckhardt SG, Diamond JR.

Cancers (Basel). 2020 Mar 19;12(3). pii: E719. doi: 10.3390/cancers12030719.

2.

Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.

Kagihara JA, Andress M, Diamond JR.

Expert Rev Precis Med Drug Dev. 2020;5(2):59-65. doi: 10.1080/23808993.2020.1730694. Epub 2020 Feb 20.

PMID:
32190733
3.

First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.

Capasso A, Bagby SM, Dailey KL, Currimjee N, Yacob BW, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Gittleman B, Hartman SJ, Tan AC, Kim J, Pitts TM, Eckhardt SG, Tentler JJ, Diamond JR.

Mol Cancer Ther. 2019 Nov;18(11):1916-1925. doi: 10.1158/1535-7163.MCT-18-1334. Epub 2019 Sep 5.

PMID:
31488700
4.

Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4.

Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM.

Clin Cancer Res. 2019 Jul 1;25(13):3946-3953. doi: 10.1158/1078-0432.CCR-18-2851. Epub 2019 Apr 2.

PMID:
30940654
5.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
6.

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.

Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG.

J Immunother Cancer. 2019 Feb 8;7(1):37. doi: 10.1186/s40425-019-0518-z.

7.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.

Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J.

JAMA Oncol. 2019 Mar 1;5(3):334-342. doi: 10.1001/jamaoncol.2018.5152.

8.

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.

Weiss J, Afghahi A, Shagisultanova E, Diamond JR.

Oncology (Williston Park). 2018 Oct 15;32(10):513-5. No abstract available.

9.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC.

Invest New Drugs. 2019 Jun;37(3):461-472. doi: 10.1007/s10637-018-0665-y. Epub 2018 Sep 19.

PMID:
30229512
10.

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.

Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S.

Oncologist. 2018 Dec;23(12):1409-e140. doi: 10.1634/theoncologist.2018-0315. Epub 2018 Aug 23.

11.

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.

Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD.

Breast Cancer Res. 2018 Aug 2;20(1):82. doi: 10.1186/s13058-018-1014-y.

12.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.

Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S.

Anticancer Drugs. 2018 Oct;29(9):827-838. doi: 10.1097/CAD.0000000000000673.

13.

A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.

Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JR.

Oncology (Williston Park). 2018 Jun;32(6):298-302. No abstract available.

14.

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.

Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR.

Front Oncol. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094. eCollection 2017.

15.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

16.

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.

Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM.

Invest New Drugs. 2017 Oct;35(5):627-633. doi: 10.1007/s10637-017-0444-1. Epub 2017 Mar 10.

17.

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.

Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ.

Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20.

PMID:
28105566
18.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

19.

Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.

Owsley J, Jimeno A, Diamond JR.

Drugs Today (Barc). 2016 Feb;52(2):119-29. doi: 10.1358/dot.2016.52.2.2440528. Review.

PMID:
27092341
20.

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G.

Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693. Epub 2016 Jan 28.

21.

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC.

BMC Genomics. 2015;16 Suppl 12:S2. doi: 10.1186/1471-2164-16-S12-S2. Epub 2015 Dec 9.

22.

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.

Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S.

Invest New Drugs. 2015 Jun;33(3):691-9. doi: 10.1007/s10637-015-0236-4. Epub 2015 Apr 21.

PMID:
25895965
23.

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR.

Mol Cancer Ther. 2015 May;14(5):1117-29. doi: 10.1158/1535-7163.MCT-14-0538-T. Epub 2015 Mar 10.

24.

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.

Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A.

Clin Cancer Res. 2015 Jun 15;21(12):2695-703. doi: 10.1158/1078-0432.CCR-14-2797. Epub 2015 Feb 27.

25.

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.

Davis SL, Eckhardt SG, Tentler JJ, Diamond JR.

Ther Adv Med Oncol. 2014 May;6(3):88-100. doi: 10.1177/1758834013519843. Review.

26.

Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.

Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR.

PLoS One. 2014 Feb 5;9(2):e86532. doi: 10.1371/journal.pone.0086532. eCollection 2014.

27.

Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.

Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P.

Neuro Oncol. 2014 Jul;16(7):1006-9.

28.

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A.

Clin Cancer Res. 2014 Mar 15;20(6):1656-65. doi: 10.1158/1078-0432.CCR-13-2506. Epub 2014 Feb 3.

29.

From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.

Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG.

J Natl Cancer Inst. 2013 Oct 2;105(19):1441-56. doi: 10.1093/jnci/djt209. Epub 2013 Sep 19. Review.

30.

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.

Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR.

J Clin Oncol. 2013 Jun 1;31(16):e254-8. doi: 10.1200/JCO.2012.46.4289. Epub 2013 Apr 22. No abstract available.

31.

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ.

Clin Cancer Res. 2013 Jan 1;19(1):291-303. doi: 10.1158/1078-0432.CCR-12-1611. Epub 2012 Nov 7.

32.

Medullary thyroid cancer and pseudocirrhosis: case report and literature review.

Harry BL, Smith ML, Burton JR Jr, Dasari A, Eckhardt SG, Diamond JR.

Curr Oncol. 2012 Feb;19(1):e36-41. doi: 10.3747/co.19.840.

33.

Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.

Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI.

Clin Cancer Res. 2011 Feb 15;17(4):849-60. doi: 10.1158/1078-0432.CCR-10-2144. Epub 2010 Dec 3.

34.

Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.

Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, Diamond JR, Fletcher GC, Bray MR, Eckhardt SG.

Clin Cancer Res. 2010 Jun 1;16(11):2989-2998. doi: 10.1158/1078-0432.CCR-10-0325. Epub 2010 Apr 20.

35.

BRCA in breast cancer: from risk assessment to therapeutic prediction.

Diamond JR, Borges VF, Eckhardt SG, Jimeno A.

Drug News Perspect. 2009 Dec;22(10):603-8. doi: 10.1358/dnp.2009.22.10.1440985. Review.

PMID:
20140280
36.

Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state.

Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF.

Oncology (Williston Park). 2009 Aug;23(9):784-91.

37.

Hepatic complications of breast cancer.

Diamond JR, Finlayson CA, Borges VF.

Lancet Oncol. 2009 Jun;10(6):615-21. doi: 10.1016/S1470-2045(09)70029-4. Review.

PMID:
19482250
38.

Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats.

Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR.

Kidney Int. 2001 Dec;60(6):2087-96.

39.

Chemokine expression in the obstructed kidney.

Crisman JM, Richards LL, Valach DP, Franzoni DF, Diamond JR.

Exp Nephrol. 2001;9(4):241-8.

PMID:
11423723
40.

Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects.

Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE.

Diabetologia. 2000 May;43(5):673-80.

PMID:
10855543
41.

Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells.

Ricardo SD, Franzoni DF, Roesener CD, Crisman JM, Diamond JR.

Am J Physiol Renal Physiol. 2000 May;278(5):F708-16.

42.

Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance.

Elkeles RS, Diamond JR, Anyaoku V, Hughes C, Richmond W.

Atherosclerosis. 1999 Sep;146(1):195-6. No abstract available.

PMID:
10487504
43.

Chemokines and renal inflammation in proteinuric disorders: searching for the inciting stimulus.

Crisman JM, Ricardo SD, Diamond JR.

J Lab Clin Med. 1999 Jan;133(1):13-4. Review. No abstract available.

PMID:
10385476
44.
45.

Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat.

Diamond JR, Kreisberg R, Evans R, Nguyen TA, Ricardo SD.

Kidney Int. 1998 Nov;54(5):1501-9.

46.

The role of macrophages and reactive oxygen species in experimental hydronephrosis.

Ricardo SD, Diamond JR.

Semin Nephrol. 1998 Nov;18(6):612-21. Review.

PMID:
9819152
47.

Mechanisms of interstitial fibrosis in obstructive nephropathy.

Diamond JR, Ricardo SD, Klahr S.

Semin Nephrol. 1998 Nov;18(6):594-602. Review.

PMID:
9819150
48.

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.

Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD.

Diabetes Care. 1998 Apr;21(4):641-8.

PMID:
9571357
49.

Ureteral obstruction as a complication of renal transplantation: a review.

Berger PM, Diamond JR.

J Nephrol. 1998 Jan-Feb;11(1):20-3. Review.

PMID:
9561481

Supplemental Content

Loading ...
Support Center